Recombinant DNA Advisory Committee - 09/14-15/92 
Others: 
Paul Aebersold, Food and Drug Administration 
James Barrett, Genetic Therapy, Inc. 
Mark Beminger, Life Technologies, Inc. 
Malcolm Brenner, St. Judes Childrens Hospital 
Vickers Burdett, Duke University 
Barrie Carter, Targeted Genetics 
Kenneth Cartwright, Alteon, Inc. 
Yawen Chang, Genetic Therapy, Inc. 
Valentina Ciccarone, Life Technologies, Inc. 
Albert Deisseroth, MD Anderson Cancer Research Center 
Wanda De Vlaminck, Somatix Therapy, Inc. 
Suzanne Forry-Schaudies, Genetic Therapy, Inc. 
Jeffrey Fox, ASM News 
Marianne Grossman, University of Michigan 
Russell Herndon, Genzyme Corporation 
Markus Hunkeler, Life Technologies, Inc. 
John Jaugstetter, Genentech 
Joel Jessee, Life Technologies, Inc. 
Joseph Kozlovac, University of Maryland 
Maryann Krane, Genzyme Corporation 
Karen Lee, National Museum of American History 
Peter Liljestrom, Karollnska Institute 
Michael Lotze, University of Pittsburgh 
Charles McCarthy, Retired NIH 
Gerard McGarrity, Genetic Therapy, Inc. 
Bonnie Mills, Baxter Health Care 
Robert Moen, Genetic Therapy, Inc. 
Ann Montgomery, FDC Reports 
Richard Moscicki, Genzyme Corporation 
Tapas Mukhopadhyay, MD Anderson Cancer Research Center 
James Neel, University of Michigan Medical Center 
Stephen Pijar, University of Maryland 
Rex Rhein, Biotechnology Newswatch 
Jack Roth, MD Anderson Cancer Research Center 
John Russick, National Museum of American History 
G. Terry Sharrer, National Museum of American History 
Tomiko Shimada, Ambiance Awareness International 
Friedrich Schuening, Fred Hutchinson Cancer Research Center 
Jonathan Simons, Johns Hopkins University 
Alan Smith, Genzyme Corporation 
Recombinant DNA Research, Volume 16 
[219] 
